Olivares-Illana, VanesaRodríguez-Romero, AdelaBecker, IngeborgBerzunza, MiriamGarcía, JuventinoPérez-Montfort, RuyCabrera, NallelyLópez Calahorra, FranciscoTuena de Gómez Puyou, MarietaGómez-Puyou, Armando2016-02-152016-02-152007-10-311935-2735https://hdl.handle.net/2445/69412Chagas disease affects around 18 million people in the American continent. Unfortunately, there is no satisfactory treatment for the disease. The drugs currently used are not specific and exert serious toxic effects. Thus, there is an urgent need for drugs that are effective. Looking for molecules to eliminate the parasite, we have targeted a central enzyme of the glycolytic pathway: triosephosphate isomerase (TIM). The homodimeric enzyme is catalytically active only as a dimer. Because there are significant differences in the interface of the enzymes from the parasite and humans, we searched for small molecules that specifically disrupt contact between the two subunits of the enzyme from Trypanosoma cruzi but not those of TIM from Homo sapiens (HTIM), and tested if they kill the parasite.8 p.application/pdfengcc-by (c) Olivares-Illana, Vanesa et al., 2007http://creativecommons.org/licenses/by/3.0/esMalaltia de ChagasChagas' diseaseinfo:eu-repo/semantics/article5507362016-02-15info:eu-repo/semantics/openAccess17989778